#95 Landmark Clinical Evidence
Peer-reviewed human research with direct implications for cannabis medicine practice.
# Clinical Summary This review examines formulation and fabrication strategies for oral mucosal delivery of cannabinoids, which bypasses first-pass hepatic metabolism and offers potential advantages over oral administration in terms of onset time and bioavailability predictability. The authors evaluate various approaches including sublingual films, sprays, lozenges, and mucoadhesive systems, comparing their pharmacokinetic profiles and practical feasibility for clinical use. Oral mucosal delivery may provide faster symptom relief and more consistent dosing compared to traditional oral cannabis products, which is particularly relevant for patients requiring rapid-onset effects such as those managing acute pain or seizures. However, the review also identifies significant challenges including variable mucosal permeability, difficulty achieving consistent drug loading, and the need for taste masking and patient acceptability optimization. Clinicians prescribing cannabinoids should be aware that emerging oral mucosal formulations may offer improved pharmacokinetic control compared to conventional edibles, though these products remain largely investigational and are not yet standardized in most clinical settings. For patients, understanding that alternative delivery methods under development could provide faster and more predictable effects may help set appropriate expectations while current oral and inhaled options remain the primary available routes.
“Oral mucosal delivery systems represent a genuine advance for cannabis medicine because they bypass hepatic first-pass metabolism, which means patients achieve more predictable blood levels and therapeutic effects at lower doses, something we’ve struggled with in clinical practice for years.”
🧴 This review examines oral mucosal delivery systems for cannabinoids, exploring formulation strategies designed to improve bioavailability and onset of action compared to traditional ingestion methods. While these approaches show promise in preclinical and early clinical settings, clinicians should recognize that mucosal delivery systems remain largely investigational and few have achieved robust clinical validation or regulatory approval. The heterogeneity of formulation technologies, variability in individual oral mucosal physiology, and lack of standardized bioequivalence data complicate direct comparison of products and prediction of patient outcomes. Additionally, the wide range of cannabinoid ratios and concentrations under development means that existing dosing guidance may not apply reliably to novel delivery systems. Clinicians considering cannabinoid therapies for their patients should remain cautious about newer mucosal formulations, prioritize products with published pharmacokinetic data and clear labeling, and counsel patients that faster
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it: